JACC: Heart Failure Editor's Update, May 2018
HEART FAILURE RESEARCH at ACC.18
Heart failure research was well represented at ACC.18. The Eugene Braunwald Keynote Lecture on “The Relationship Between Heart Failure and Type 2 Diabetes” by Dr. John J.V. McMurray, Professor of Cardiology at the University of Glasgow, was excellent and insightful. The session began with each Editor-in-Chief of the JACC journals briefly presenting what we identified as our top papers from 2017, which included my presentation on The Best of JACC Heart Failure: Practice Changing Research (video begins minute 24) .
Below is a list of papers our Associate Editor team selected as most impactful among the many outstanding papers published in 2017.
- Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial
Andrew P. Ambrosy, Lukasz P. Cerbin, et al
- Associations Between Short or Long Length of Stay and 30-Day Readmission and Mortality in Hospitalized Patients With Heart Failure
Maneesh Sud, Bing Yu, et al
- Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy
Julia Cadrin-Tourigny, Azadeh Shohoudi, et al
- Body Mass Index and Cardiorespiratory Fitness in Mid-Life and Risk of Heart Failure Hospitalization in Older Age: Findings From the Cooper Center Longitudinal Study
Ambarish Pandey, William K. Cornwell, et al
- Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients
David E. Lanfear, Joseph J. Gibbs, et al
- Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results
Randall C. Starling, Jerry D. Estep, et al
- The Affordable Care Act Medicaid Expansion Correlated With Increased Heart Transplant Listings in African-Americans But Not Hispanics or Caucasians
Khadijah Breathett, Larry A. Allen, et al
- Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure
Amrut V. Ambardekar, Jennifer T. Thibodeau, et al
2017 YOUNG AUTHOR WINNERS
- A New Clinically Applicable Measure of Functional Status in Patients With Heart Failure: The 60-Foot Walk Test
Kristie M. Harris, MS, The Ohio State University
Mentor: David S. Krantz, PhD, Uniformed Services University of the Health Sciences
- A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study
Gordon R. Reeves (right), MD, MPT, Sidney Kimmel Medical College at Thomas Jefferson University
Mentor: David J. Whellan (left), MD, MHS, Thomas Jefferson University
SIMULTANEOUS PUBLICATIONS FROM ACC.18
- Sudden Death in Heart Failure with Preserved Ejection Fraction: A Competing Risks Analysis from the TOPCAT Trial
Muthiah Vaduganathan, Brian L. Claggett, et al
Sudden death was shown to account for approximately 20% of deaths in HFpEF, with male gender and insulin-treated diabetes predicting higher risk for sudden death or aborted cardiac arrest. The data from this study may guide future efforts to prevent sudden death in HFpEF.
- Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
Muthiah Vaduganathan, Brian Claggett, et al
This research showed that therapy-related changes in natriuretic peptides (NPs) appeared to be modestly correlated with longer-term therapeutic effects on hospitalization for heart failure, but not with effects on all-cause mortality, suggesting caution regarding the use of NPs in phase II trials for decision-making regarding phase III trials.
- Will biomarkers succeed as a surrogate endpoint in heart failure trials?
James L. Januzzi
An Editorial Comment which suggests that additional studies are necessary before cardiac biomarkers can be used as acceptable endpoints.
I have to ask Jim Januzzi, Mike Felker and their biomarker colleagues - why hasn't the heart failure field advanced further with biomarkers as surrogate endpoints (like LDL) and have we advanced at all with results such as the GUIDE-IT study? Let's hear from you on this topic.
I look forward to highlighting more of our excellent publications and highlighted topics in next month's issue.